Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629030 | 0.77 | PIK3CG (0.57) | SMPD3PIK3CGAXLALDH1A1APOBEC3A | |
| SCHEMBL31211823 | 0.74 | SMPD3 (0.46) | SMPD3PIK3CGALDH1A1APOBEC3AIRAK4 | |
| SCHEMBL31165797 | 0.73 | AXL (0.47) | SMPD3PIK3CGAXLAPOBEC3AIRAK4 | |
| SCHEMBL15336872 | 0.73 | SMPD3 (0.47) | SMPD3PIK3CGAXLJAK2JAK3 | |
| SCHEMBL30852918 | 0.73 | PIK3CG (0.41) | SMPD3PIK3CGAXLALDH1A1APOBEC3A | |
| SCHEMBL31211903 | 0.71 | ALDH1A1 (0.42) | SMPD3ALDH1A1APOBEC3AHPGD | |
| SCHEMBL31259841 | 0.68 | SMPD3 (1.00) | SMPD3AXLALDH1A1IRAK4CDK2 | |
| SCHEMBL17460398 | 0.67 | BRD4 (0.45) | ALDH1A1APOBEC3AIRAK4HPGD | |
| SCHEMBL17460383 | 0.67 | HPGD (0.50) | ALDH1A1APOBEC3AIRAK4HPGD | |
| SCHEMBL17460376 | 0.66 | KCNQ3 (0.41) | PIK3CGALDH1A1APOBEC3AIRAK4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885PIK3CG 354/4885AXL 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.